What is the recommended management of rheumatoid arthritis?

Management of Rheumatoid Arthritis

Start methotrexate immediately at diagnosis as the anchor DMARD, escalating to 15-25 mg/week, combined with short-term low-dose glucocorticoids (≤10 mg/day prednisone) for up to 6 months, then rapidly taper steroids while monitoring disease activity every 1-3 months until achieving remission or low disease activity. 1, 2, 3

Initial Treatment Strategy

Methotrexate is the first-line therapy for all newly diagnosed RA patients unless contraindicated. 1, 2, 4

• Start methotrexate at 15 mg/week and escalate to 20-25 mg/week or maximum tolerated dose within the first few weeks 1, 3
• If oral methotrexate causes gastrointestinal intolerance, switch to subcutaneous/parenteral administration before abandoning the drug 5, 6
• Add folic acid supplementation to reduce methotrexate-related adverse effects 7
• Combine methotrexate with low-dose glucocorticoids (≤10 mg/day prednisone equivalent) for up to 6 months, then taper as rapidly as clinically feasible 1, 2, 4

If methotrexate is contraindicated, use leflunomide or sulfasalazine as alternative first-line csDMARDs. 2, 4

Disease Activity Monitoring and Treatment Targets

Assess disease activity every 1-3 months during active disease using validated composite measures (DAS28, SDAI, or CDAI). 2, 3, 4

• The therapeutic target is sustained remission or low disease activity for all RA patients 3, 4
• Monitor tender and swollen joint counts, patient and physician global assessments, ESR, and CRP at each visit 8
• Continue frequent monitoring until treatment target is achieved, then monitor less frequently in sustained remission 2, 4

Escalation to Biologic or Targeted Synthetic DMARDs

If the treatment target is not achieved within 3-6 months with methotrexate plus glucocorticoids, and poor prognostic factors are present (autoantibodies, high disease activity, early erosions, or failure of two csDMARDs), add a bDMARD or tsDMARD to the csDMARD. 1, 2, 4

Choice of bDMARD or tsDMARD:

• TNF inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab including biosimilars), abatacept, tocilizumab, sarilumab, or rituximab can be added in combination with methotrexate 1, 4
• JAK inhibitors (tofacitinib, baricitinib, filgotinib, upadacitinib) may be considered after careful evaluation of risks for major cardiovascular events (MACEs), malignancies, and thromboembolic events, particularly in patients with cardiovascular risk factors 1, 4
• All bDMARDs should be used in combination with methotrexate rather than as monotherapy for optimal efficacy 1, 4

Common Pitfall:

Do not delay escalation to bDMARDs or tsDMARDs in patients with poor prognostic factors, as early aggressive treatment prevents irreversible structural damage and long-term disability 3, 4

Management After First bDMARD/tsDMARD Failure

If the first bDMARD or tsDMARD fails, switch to another bDMARD from a different or the same class, or to a tsDMARD (considering safety risks). 2, 4

• Switching mechanism of action is generally preferred after unsuccessful biologic treatment 5, 4
• Any bDMARD or tsDMARD can be used in this phase, with selection based on patient comorbidity profile, safety considerations, and preferences 1, 4

Tapering in Sustained Remission

Once sustained remission or low disease activity is achieved, cautiously taper glucocorticoids first, followed by potential dose reduction of bDMARDs or tsDMARDs, but do not stop DMARDs completely. 2, 4

• Taper glucocorticoids as the first step once remission is achieved 2, 4
• After sustained remission on stable therapy, consider tapering (but not stopping) bDMARDs or tsDMARDs 4
• Methotrexate should be continued even in sustained remission to maintain disease control 4

Special Considerations for High-Risk Populations

Assess cardiovascular risk annually using national guidelines with a 1.5 multiplication factor for RA patients meeting high-risk criteria. 3

• Screen for treatment-related complications including cardiovascular risk factors, infections, and bone health 3
• Optimize bone health with calcium, vitamin D supplementation, and bisphosphonates when indicated, particularly in glucocorticoid-exposed patients 3
• For patients with RA-associated interstitial lung disease or vasculitis, specific treatment modifications may be necessary 5
• In patients with liver disease, heart failure, lymphoproliferative disorders, previous serious infections, or nontuberculous mycobacterial lung disease, DMARD selection requires careful risk-benefit assessment 1

Adjunctive Non-Pharmacologic Interventions

• Dynamic exercises and occupational therapy should be incorporated as adjuncts to drug treatment 8
• Patient education about disease, outcomes, and treatment is essential 8
• Education programs addressing pain coping, disability management, work maintenance, and social participation may be used as adjunct interventions 8